Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?

Although around 80% of endometrial cancers are diagnosed at early stages and present with a 5-year survival rate exceeding 95%, patients with advanced and recurrent disease show a poor prognosis and low response rates to standard chemotherapy. In the era of targeted therapy, the great advances in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Musacchio, Lucia, Boccia, Serena Maria, Caruso, Giuseppe, Santangelo, Giusi, Fischetti, Margherita, Tomao, Federica, Perniola, Giorgia, Palaia, Innocenza, Muzii, Ludovico, Pignata, Sandro, Benedetti Panici, Pierluigi, Di Donato, Violante
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356971/
https://www.ncbi.nlm.nih.gov/pubmed/32503218
http://dx.doi.org/10.3390/jcm9061721

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356971/
https://www.ncbi.nlm.nih.gov/pubmed/32503218
http://dx.doi.org/10.3390/jcm9061721

Ejemplares similares